Streetbeat News

FEMY

Femasys Inc.

https://www.femasys.com

Industry

Medical - Instruments & Supplies

Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

Open

0.99

Mkt cap

22M

Volume

141K

High

1.00

P/E Ratio

-1.13

52-wk high

2.40

Low

0.95

Div yield

N/A

52-wk low

0.73

AERWINS Technologies Inc. (AWIN) shares rose by 90.2% in pre-market trading as the company is considering strategic alternatives for non-core operations. Other companies that saw a rise in pre-market trading include RVL Pharmaceuticals (RVLP), Better Choice Company (BTTR), Bionomics Limited (BNOX), Athena Consumer Acquisition Corp. (ACAQ), EMCORE Corporation (EMKR), Syndax Pharmaceuticals (SNDX), Bitfarms Ltd. (BITF), Femasys Inc. (FEMY), and Oragenics, Inc. (OGEN). On the other hand, SmileDirectClub, Inc. (SDC) filed for bankruptcy, causing its shares to fall by 64.1%. Other companies that saw a fall in pre-market trading include Intelligent Bio Solutions Inc. (INBS), Context Therapeutics Inc. (CNTX), Nexalin Technology, Inc. (NXL), ReShape Lifesciences Inc. (RSLS), Brooge Energy Limited (BROG), Danaher Corporation (DHR), Siyata Mobile Inc. (SYTA), Grom Social Enterprises Inc (GROM), and Bolt Biotherapeutics Inc (BOLT).

Portfolio Pulse from Lisa Levin

October 02, 2023 | 12:11 pm

Several stocks experienced significant price movements in Friday's mid-day trading session. Blue Apron Holdings (APRN) surged 133.5% after announcing an acquisition agreement with Wonder Group. OpGen (OPGN) jumped 109% after requesting to withdraw its registration statement. Novo Integrated Sciences (NVOS) gained 66.3% after signing a $1 billion Master Collateral Transfer Agreement with Blacksheep Trust. SeaStar Medical Holding (ICU) rose 35% after being granted Breakthrough Device Designation by the FDA. On the downside, The Glimpse Group (VRAR) dipped 42.5% after reporting a wider FY23 loss, and Capricor Therapeutics (CAPR) fell 41.4% after announcing a $23 million registered direct offering.

Portfolio Pulse from Lisa Levin

September 29, 2023 | 6:10 pm

During Friday's intraday session, several healthcare stocks experienced significant movements. Femasys, OpGen, Novo Integrated Sciences, SeaStar Medical Holding, Evoke Pharma, and Structure Therapeutics saw their stocks rise, with Femasys leading the gainers with a 104.9% increase. On the other hand, Capricor Therapeutics, Reshape Lifesciences, Vaccinex, Tonix Pharmaceuticals, Corcept Therapeutics, and Baudax Bio saw their stocks fall, with Capricor Therapeutics leading the losers with a 41.4% decrease.

Portfolio Pulse from Benzinga Insights

September 29, 2023 | 5:31 pm

Femasys Inc. (NASDAQ:FEMY) stock is trading higher after HC Wainwright maintained a Buy rating and raised its price target from $5 to $13. The stock has seen heavy trading volume, with over 66 million shares traded, far exceeding the 100-day average of 7.256 million shares. Femasys is a biomedical company focused on women's healthcare solutions.

Portfolio Pulse from Erica Kollmann

September 29, 2023 | 3:21 pm

HC Wainwright has maintained a Buy rating on Femasys and raised its price target from $5 to $13, leading to a rise in Femasys' stock price.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 2:22 pm

Structure Therapeutics announced positive results from Phase 1b clinical study of oral GLP-1 receptor agonist GSBR-1290. HC Wainwright & Co. maintains a buy rating on Femasys and raises the price target to $13. No specific news for NKE.

Portfolio Pulse from ryanfaloona@benzinga.com

September 29, 2023 | 12:42 pm

Several stocks have shown significant movement in pre-market trading. Notable gainers include RVL Pharmaceuticals, Novo Integrated Sciences, Polished.com, OpGen, Brooge Energy, iSun, T2 Biosystems, OPKO Health, Better Therapeutics, and NIKE. On the other hand, The Glimpse Group, Tonix Pharmaceuticals, Vaccinex, Bionomics, FLJ Group, ReShape Lifesciences, Femasys, Baudax Bio, Quince Therapeutics, and Ostin Technology Group have seen a decrease in their share prices.

Portfolio Pulse from Lisa Levin

September 29, 2023 | 12:15 pm

Several analyst forecasts were released on Friday, affecting the stocks of Accenture, Editas Medicine, NIKE, The Sherwin-Williams Company, Illumina, Restaurant Brands International, Femasys, CarMax, Flowserve Corporation, Domino's Pizza, and Trimble. The forecasts included price target changes and rating adjustments.

Portfolio Pulse from Lisa Levin

September 29, 2023 | 12:03 pm

HC Wainwright & Co. analyst Emily Bodnar maintains a 'Buy' rating on Femasys (NASDAQ:FEMY) and raises the price target from $5 to $13.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 10:26 am

During Thursday's intraday session, several healthcare stocks experienced significant movements. Bionomics (BNOX), Baudax Bio (BXRX), Femasys (FEMY), Axcella Health (AXLA), Organogenesis Hldgs (ORGO), and Aytu BioPharma (AYTU) saw increases, with Bionomics leading with a 261.4% rise. On the other hand, Brainstorm Cell (BCLI), Renalytix (RNLX), Sharps Technology (STSS), ACADIA Pharmaceuticals (ACAD), Avalo Therapeutics (AVTX), and Biophytis (BPTS) experienced decreases, with Brainstorm Cell falling by 55.3%.

Portfolio Pulse from Benzinga Insights

September 28, 2023 | 5:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.